Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects

Transfusion and Apheresis Science

Volumn 52, Issue 2, 2015, Pages 240-244

  Irsch, Johannes ^a   Seghatchian, Jerard ^b  

^a Cerus Europe BV   (Netherlands)

^b International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD ANALYSIS; BLOOD COMPONENT; BLOOD GROUP SYSTEM; BLOOD SAFETY; BLOOD TRANSFUSION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DEVICE SAFETY; EMERGENCY TREATMENT; HEMOSTASIS; HUMAN; LEUKOCYTE; PATHOGEN CLEARANCE; PATHOGEN REDUCTION SYSTEM; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; REVIEW; THERAPY EFFECT; VIRUS INACTIVATION; APHERESIS; BLOOD BANK; BLOODBORNE BACTERIUM; CHEMISTRY; COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; DISINFECTION; EQUIPMENT DESIGN; ISOLATION AND PURIFICATION; PLASMA; PORTUGAL; PROCEDURES; STANDARDS; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSMISSION; ULTRAVIOLET RADIATION;

AMOTOSALEN; ANTIINFECTIVE AGENT; BLOOD CLOTTING FACTOR; FUROCOUMARIN DERIVATIVE;

ANTI-INFECTIVE AGENTS; BLOOD BANKS; BLOOD COAGULATION FACTORS; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DISINFECTION; EQUIPMENT DESIGN; FUROCOUMARINS; HUMANS; PLASMA; PLATELET TRANSFUSION; PORTUGAL; ULTRAVIOLET RAYS;

EID: 84930478312     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2015.02.013     Document Type: Review

References (35)

1. Hambleton J., Wages D., Radu-Radulescu L., Adams M., Mackenzie M., Shafer S., et al. Transfusion 2002, 42:1302-1307.
2. Dodd R.Y., Leiby D. Emerging infectious threats to the blood supply. Annu Rev Med 2004, 55:191-207.
3. Dodd R. Curr Opin Hematol 2007, 14:671-676.
4. Stramer S., Blaine Hollinger F., Katz L., Kleinman S., Metzel P., Gregory K., et al. Transfusion 2009, 49:1S-29S.
5. Klein H., Anderson D., Bernardi M., Cable R., Hoch J., Robitaille N., et al. Transfusion 2008, 48:697-705.
6. Singh Y., Sawyer L., Pinkoski L., Dupuis K., Hsu J., Lin L., et al. Transfusion 2006, 46:1168-1177.
7. Irsch J., Lin L. Transfus Med Hemother 2011, 38:19-31.
8. Wollowitz S. Semin Hematol 2001, 38(4):4-11.
9. Irsch J., Pinkoski L., Corash L., Lin L. Vox Sang 2010, 98:47-55.
10. Hellstern P., Solheim B. Transfus Med Hemother 2011, 38:65-70.
11. Marschner S., Goodrich R. Transfus Med Hemother 2011, 38:8-18.
12. Seghatchian J., Struff W., Reichenberg S. Transfus Med Hemother 2011, 38:55-64.
13. Prowse C. Vox Sang 2012, 10.1111/j.1423-0410.2012.01662.x.
14. Feys H., Van Aelst B., Devreese K., Devloo R., Coene J., Vandekerckhove P., et al. Vox Sang 2013, 10.1111/vox.12106.
15. Coene J., Devreese K., Sabot B., Feys H., Vandekerckhove P., Compernolle C. Transfusion 2013, 10.1111/trf.12460.
16. Ciaravino V., McCullough T., Cimino G., Sullivan T. Vox Sang 2003, 85:171-182.
17. Heiden M., Seitz R. ISBT Sci Ser 2010, 5:279-281.
18. Schlenke P., Hervig T., Isola H., Wiesel M.L., Kientz D., Pinkoski L., et al. Transfusion 2008, 48:697-705.
19. Osselaer J.C., Debry C., Goffaux M., Pineau J., Calomme G., Dubuc E., et al. Transfusion 2007, 10.1111/j.1537-2995.2007.01488.x.
20. Mintz P.D., Bass N.M., Petz L.D., Steadman R., Streiff M., McCullough J., et al. Blood 2006, 107:3753-3760.
21. Mintz P.D., Neff A., MacKenzie M., Goodnough L.T., Llyer C., Kessler C., et al. Transfusion 2006, 46:1693-1704.
22. de Alarcon P., Benjamin R., Dugdale M., Kessler C., Shopnick R., Smith P., et al. Transfusion 2005, 45:1362-1372.
23. Cinqualbre J., Kientz D., Remy E., Huanq N., Corash L., Cazenave J.P. Transfusion 2015, in press.
24. Herbrecht R., et al. Manuscript in preparation, 2015.
25. Cazenave J.P., Waller C., Kientz D., Mendel I., Lin L., Jacquet M., et al. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2009, 50(6). 10.1111/j.1537-2995.2009.02579.x.
26. Afssaps Rapport Annuel Hemovigilance Commission Nationale d'Hemovigilancecompte-Rendu de Reunion du 1er février 2011 p 56. http://www.afssaps.fr.
27. Castro E., Pajares A., Barea L., Rodriguez P., Surribas F., Simon P., et al. Vox Sang 2009, 96(Suppl. 1):63-260.
28. Santos, et al. Manuscript in preparation, 2015.
29. Martinaud C., Ausset S., Deshayes A.V., Cauet A., Demazeau N., Sailliol A. J Trauma 2011, 71(6).
30. Mintz P.D., Avery N.L., et al. Transfusion 2000, 40(Suppl. 1). 63S.
31. Wiltshire M., Backholer L., Proffitt S., Cardigan R. Vox Sang 2013, 105(Suppl. 1):65-299.
32. Geisen C., et al. Manuscript in preparation.
33. Burnouf T., Seghatchian J. Transfus Apher Sci 2014, 51:120-125.
34. Benjamin R. Transfusion 2012, 52:9S-19S.
35. Ohlmann P., Cazenave J.P., Isola H., Gachet C. Transfusion Clinique et Biologique 2009, 16:277.